Cough syrup deaths: Pharmexcil suspends membership of Marion Biotech

The drug maker will lose some incentives due to the suspension, sources in Pharmexcil said.

"The incentives offered by the DoC (Department of Commerce) through Pharmexcil will not be extended until the suspension is revoked," sources told PTI.

Noida-based Marion Biotech, under the scanner following the death of 18 children in Uzbekistan allegedly after consuming its cough syrup, is the flagship firm of Emenox group which also has a presence in real estate and hospitals.

Read also: Maiden Pharma responsible for deaths of 70 children from acute kidney injury: Gambian Parliamentary committee

"You are further advised to investigate the reasons of the alleged Serious Adverse Events at your end and update us with your findings at the earliest to take necessary further action. Upon failure of submission of requested information by 29th Dec 2022, your Registration cum Membership Certificates (RCMC) will be suspended without any further notice," Pharmexcil said in its notice to Marion Biotech on December 28.

Marion Biotech registered with Pharmexcil as a small-scale manufacturer since 2010 and merchant exporter since 2016.

Read also: Maiden Pharma responsible for deaths of 70 children from acute kidney injury: Gambian Parliamentary committee

"Alleged supply of substandard medicines by the company that led to the death of 18 children has brought bad reputation to the Indian pharma industry and also likely to have an impact on the trust of international agencies on Indian pharma exports," the export body further said.

Marion Biotech, does not sell cough syrup, 'Doc-1 Max', in India, and its only export has been to Uzbekistan.

Read also: India seeks details of Uzbekistan's investigation into cough syrup deaths case